NYSE | TSX: ACB

 Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE: ACB) ( TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the ” Meeting “) held on Thursday, November 12, 2020 by virtual webcast. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 48,828,603, representing 40.34% of Aurora’s issued and outstanding common shares.


All of the matters put forward before shareholders for consideration and approval, as set out in the Company’s Management Information Circular dated September 28, 2020 , were approved by the requisite majority of votes cast at the Meeting. The details of the voting results for the election of directors are set out below:

Nominee

Votes For

Votes Withheld

Miguel Martin

9,114,731
(90.05%)

1,007,078

(9.95%)

Michael Singer

8,327,088

(82.27%)

1,794,722

(17.73%)

Ron Funk

8,920,391

(88.13%)

1,201,419

(11.87%)

Norma Beauchamp

8,901,696

(87.95%)

1,220,113

(12.05%)

Margaret Shan Atkins

8,965,142
(88.57%)

1,156,667

(11.43%)

Adam Szweras

8,642,769
(85.39%)

1,479,040
(14.61%)

Michael Detlefsen

9,009,767

(89.01%)

1,112,043

(10.99%)

Lance Friedmann

8,894,788

(87.88%)

1,227,022

(12.12%)

Shareholders also approved the following matters:

  • appointment of KPMG LLP as auditors of the Company for the ensuing year;
  • renewal of the Company’s 10% “rolling” stock option plan;
  • adoption of the Company’s fixed performance share unit plan;
  • an amendment to each of the Company’s fixed restricted share unit plan and fixed deferred share unit plan to increase the number of common shares issuable under each plan; and
  • a non-binding advisory resolution on the Company’s approach to executive compensation

The Company has filed a report of voting results on all resolutions voted on at the Meeting on www.sedar.com

About Aurora

Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquartered in Edmonton, Alberta , Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company’s brand portfolio includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched. For more information, please visit our website at www.auroramj.com .

Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.

Forward Looking Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/aurora-announces-results-of-2020-annual-general-and-special-meeting-301173281.html

SOURCE Aurora Cannabis Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2020/16/c5177.html

News Provided by Canada Newswire via QuoteMedia

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less